Valuation: Insmed Incorporated

Market Cap 21.37B 18.58B 17.29B 15.88B 29.98B 2,040B 30.45B 204B 80B 1,016B 80.26B 78.5B 3,406B P/E 2026 *
-38.6x
P/E 2027 * 196x
Enterprise Value 20.81B 18.09B 16.84B 15.46B 29.19B 1,986B 29.64B 198B 77.89B 989B 78.15B 76.43B 3,316B EV / Sales 2026 *
12.2x
EV / Sales 2027 * 7.35x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insmed Incorporated

1 day-2.85%
1 week-7.78%
1 month-7.52%
3 months-27.68%
6 months-37.15%
Current year-43.35%
1 week 97.05
Extreme 97.05
107.37
1 month 97.05
Extreme 97.05
119.54
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 20.94
Extreme 20.94
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
7/23/26 Fiscal year

Chief Executive Officer

32,100 0.0148%
7/9/26 Fiscal year

Chief Executive Officer

32,097 0.0148%
7/6/26 Fiscal year

Chief Technology Officer

36,906 0.0170%
Change 5-day change 1-year change 3-year change Capi.($)
-2.85%-7.78%-8.09%+346.36% 21.37B
+2.35%+2.74%+33.41%+79.20% 56.54B
-0.21%-7.38%+25.34%+63.02% 53.6B
-2.44%+1.40%-15.74%-16.80% 22.91B
+2.49%-0.92%+20.31%-12.15% 20.27B
+0.79%-1.06%+29.29%-33.32% 17.56B
+0.58%-5.88%+16.30%+540.37% 14.75B
-5.25%-4.23%+46.41%+169.05% 13.33B
+3.41%-6.61%+163.08%+280.43% 13.53B
-3.06%-1.11%+435.76%+145.22% 11.92B
Average -0.42%-3.52%+74.61%+156.14% 24.58B
Weighted average by Cap. +0.07%-2.87%+48.42%+121.20%

Financials

2026 *2027 *
Net sales 1.7B 1.48B 1.38B 1.26B 2.39B 162B 2.42B 16.22B 6.37B 80.83B 6.39B 6.25B 271B 2.78B 2.41B 2.25B 2.06B 3.89B 265B 3.96B 26.48B 10.39B 132B 10.43B 10.2B 442B
Net income -561M -488M -454M -417M -787M -53.58B -800M -5.35B -2.1B -26.68B -2.11B -2.06B -89.45B 71.64M 62.27M 57.96M 53.22M 100M 6.84B 102M 683M 268M 3.4B 269M 263M 11.42B
Net Debt -563M -489M -456M -418M -790M -53.75B -802M -5.37B -2.11B -26.76B -2.11B -2.07B -89.73B -979M -851M -792M -727M -1.37B -93.41B -1.39B -9.33B -3.66B -46.51B -3.68B -3.59B -156B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-07-31 US$98.60 -2.85% 2,902,595
26-07-30 US$101.49 -1.58% 3,363,495
26-07-29 US$103.12 -0.97% 2,195,533
26-07-28 US$104.13 -0.57% 1,945,719
26-07-27 US$104.73 -2.05% 1,899,713
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
98.60USD
Average target price
196.18USD
Spread / Average Target
+98.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock